Live
- Did Cong sink MVA in Maharashtra? Data crunching throws up interesting details
- RCB's IPL 2025 Squad: Star Players, New Additions, and Exciting Leadership Change
- Sensex settles flat at 80,004, auto shares slide
- North Korea cuts power lines installed by South Korea
- Blood-like liquid on roads in Hyderabad’s Jeedimetla sparks panic
- Detrimental to interests of people: Priyanka Chaturvedi on delay in naming Maha CM
- Ecclestone, Sciver-Brunt gain big in ICC Women's T20I Player Rankings
- 'Scam of Rs 46,300 crore in BBMP', K'taka BJP leader files complaint with ED
- Govt’s bank guarantee waiver to cut financial burden on telcos, boost digital infra: Industry
- Google App Adds Search Links to Webpages: Details
Natco partner's cancer drug gets FDA nod
Natco partner’s cancer drug gets FDA noda
Hyderabad-Natco Pharma on Monday said its marketing partner Breckenridge Pharmaceutical Inc has received approval from the US health regulator for anti-cancer drug Carfilzomib Vials
Hyderabad: Hyderabad-Natco Pharma on Monday said its marketing partner Breckenridge Pharmaceutical Inc has received approval from the US health regulator for anti-cancer drug Carfilzomib Vials.
"Breckenridge Pharmaceutical Inc. (BPI), has received approval for its abbreviated new drug application (ANDA) for Carfilzomib Vials ANDA (generic for Kyprolis), from the US Food and Drug Administration (USFDA)," Natco Pharma said in a regulatory filing. Natco has tied up with Breckenridge Pharmaceutical Inc to market the product in the US.
"The parties have received final approval for 10 mg and 60 mg strengths of the product and tentative approval for the 30 mg strength of the product," it added. Natco Pharma said based on the ANDA filing date, the company believes that it is eligible for 180 days of sole generic marketing exclusivity for the 10 mg strength and shared 180 days of generic marketing exclusivity for the 60 mg strength of the product at the time of launch.
